# RYTELO (imetelstat) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/imetelstat

> The FDA approved RYTELO (imetelstat), sponsored by GERON CORP (GERN), on September 30, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is RYTELO (imetelstat) FDA approved?

Yes. The FDA approved RYTELO (imetelstat), sponsored by GERON CORP (GERN), on September 30, 2025. SEC Form 10-Q: "The decrease in research and development expenses for the nine months ended September 30, 2025, compared to the same period in 2024, was primarily due to decreased clinical trial costs associated with a decrease of activity in our Phase 3 IMerge MDS study after FDA approval of RYTELO in 2024, as well as manufacturing and quality costs that were capitalized in the current period now that RYTELO is approved, versus being expensed in the prior period." [Calendar and source filings](https://sec-api.dev/pdufa/imetelstat)

Source: SEC Form 10-Q, accession 0000886744-25-000071, https://www.sec.gov/Archives/edgar/data/886744/000088674425000071/gern-20250930.htm (retrieved 2026-11-12). Last confirmed 2025-11-07. Cite: https://sec-api.dev/pdufa/imetelstat#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | RYTELO (imetelstat) |
| Codes | GRN163L |
| Sponsor | GERON CORP (GERN) https://sec-api.dev/companies/gern/catalysts |
| Indications | jaki relapsed/refractory myelofibrosis, To treat low- to intermediate-1 risk myelodysplastic syndromes, [Myelofibrosis](https://sec-api.dev/indications/myelofibrosis) |
| Modality | small_molecule |
| FDA designations | fast track, orphan |

## Timeline

### Jan 2023: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2025-02-27, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0000886744-26-000041): "Even though we reported positive top-line results from IMerge Phase 3 in January 2023 and received regulatory approval from the FDA in June 2024 to commercialize RYTELO in the U.S. for lower-risk MDS, the top-line results from IMerge Phase 3 are not necessarily predictive of RYTELO's activity in other indications." https://www.sec.gov/Archives/edgar/data/886744/000088674426000041/gern-20260930.htm
- SEC Form 10-Q (accession 0000886744-26-000041): "In addition, even though we reported positive top-line results from IMerge Phase 3 in January 2023, this does not ensure that any other clinical trials of imetelstat will be successful." https://www.sec.gov/Archives/edgar/data/886744/000088674426000041/gern-20260930.htm
- SEC Form 10-Q (accession 0000886744-26-000037): "Even though we reported positive top-line results from IMerge Phase 3 in January 2023 and received regulatory approval from the FDA in June 2024 to commercialize RYTELO in the U.S. for lower-risk MDS, the top-line results from IMerge Phase 3 are not necessarily predictive of RYTELO's activity in other indications, such as in relapsed/refractory MF." https://www.sec.gov/Archives/edgar/data/886744/000088674426000037/gern-20260630.htm
- SEC Form 10-Q (accession 0000886744-26-000037): "In addition, even though we reported positive top-line results from IMerge Phase 3 in January 2023, this does not ensure that any other clinical trials of imetelstat will be successful." https://www.sec.gov/Archives/edgar/data/886744/000088674426000037/gern-20260630.htm
- SEC Form 10-Q (accession 0000886744-26-000032): "Even though we reported positive top-line results from IMerge Phase 3 in January 2023 and received regulatory approval from the FDA in June 2024 to commercialize RYTELO in the U.S. for lower-risk MDS, the top-line results from IMerge Phase 3 are not necessarily predictive of RYTELO's activity in other indications, such as in relapsed/refractory MF." https://www.sec.gov/Archives/edgar/data/886744/000088674426000032/gern-20260331.htm
- SEC Form 10-Q (accession 0000886744-26-000032): "In addition, even though we reported positive top-line results from IMerge Phase 3 in January 2023, this does not ensure that any other clinical trials of imetelstat will be successful." https://www.sec.gov/Archives/edgar/data/886744/000088674426000032/gern-20260331.htm
- SEC Form 10-K (accession 0000886744-26-000008): "Even though we reported positive top-line results from IMerge Phase 3 in January 2023 and received regulatory approval from the FDA in June 2024 to commercialize RYTELO in the U.S. for lower-risk MDS, the top-line results from IMerge Phase 3 are not necessarily predictive of RYTELO's activity in other indications, such as in relapsed/ refractory MF." https://www.sec.gov/Archives/edgar/data/886744/000088674426000008/gern-20251231.htm
- SEC Form 10-K (accession 0000886744-26-000008): "In addition, even though we reported positive top-line results from IMerge Phase 3 in January 2023, this does not ensure that any other clinical trials of imetelstat will be successful." https://www.sec.gov/Archives/edgar/data/886744/000088674426000008/gern-20251231.htm
- SEC Form 10-Q (accession 0000886744-25-000071): "Even though we reported positive top-line results from IMerge Phase 3 in January 2023 and received regulatory approval from the FDA in June 2024 to commercialize RYTELO in the U.S. for lower-risk MDS, the top-line results from IMerge Phase 3 are not necessarily predictive of RYTELO's activity in other indications, such as from IMpactMF." https://www.sec.gov/Archives/edgar/data/886744/000088674425000071/gern-20250930.htm
- SEC Form 10-Q (accession 0000886744-25-000071): "In addition, even though we reported positive top-line results from IMerge Phase 3 in January 2023, this does not ensure that any other clinical trials of imetelstat will be successful." https://www.sec.gov/Archives/edgar/data/886744/000088674425000071/gern-20250930.htm
- SEC Form 10-Q (accession 0000886744-25-000052): "Even though we reported positive top-line results from IMerge Phase 3 in January 2023 and received regulatory approval from the FDA in June 2024 to commercialize RYTELO in the U.S. for lower-risk MDS, the top-line results from IMerge Phase 3 are not necessarily predictive of RYTELO's activity in other indications, such as from IMpactMF." https://www.sec.gov/Archives/edgar/data/886744/000088674425000052/gern-20250630.htm
- SEC Form 10-Q (accession 0000886744-25-000052): "In addition, even though we reported positive top-line results from IMerge Phase 3 in January 2023, this does not ensure that any other clinical trials of imetelstat will be successful." https://www.sec.gov/Archives/edgar/data/886744/000088674425000052/gern-20250630.htm

### March 14, 2024: FDA advisory committee meeting

- Status: completed, positive. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA advisory committee calendar: "The Committee will discuss new drug application (NDA) 217779 for imetelstat for injection, submitted by Geron Corporation. The proposed indication for this product is for the treatment of transfusion-dependent anemia in adult patients with low- to intermediate-1 risk myelodysplastic syndromes who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents." https://www.fda.gov/advisory-committees/advisory-committee-calendar/march-14-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-03142024
- FDA advisory committee calendar: "VOTE: Do the benefits of imetelstat outweigh its risks for the treatment of transfusion dependent anemia in adult patients with International Prognosis Scoring System (IPSS) low- to intermediate-1 risk MDS who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents? Vote Result: Yes: 12 No: 2 Abstain: 0" https://www.fda.gov/media/180262/download

### June 6, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat low- to intermediate-1 risk myelodysplastic syndromes.
- First seen 2025-02-26, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Rytelo | imetelstat | 6/6/2024 | To treat low- to intermediate-1 risk myelodysplastic syndromesDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024
- openFDA Drugs@FDA: "NDA217779 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20240606, review_priority STANDARD; sponsor_name GERON; product RYTELO (IMETELSTAT SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217779%22
- SEC Form 10-Q (accession 0000886744-26-000041): "On June 6, 2024, we announced that the FDA approved RYTELO for the treatment of adult patients with lower-risk MDS, with TD anemia requiring four or more red blood cell units over eight weeks who have not responded to, or have lost response to, or are ineligible for ESA." https://www.sec.gov/Archives/edgar/data/886744/000088674426000041/gern-20260930.htm
- SEC Form 10-Q (accession 0000886744-26-000037): "On June 6, 2024, we announced that the FDA approved RYTELO for the treatment of adult patients with lower-risk MDS, with TD anemia requiring four or more red blood cell units over eight weeks who have not responded to, or have lost response to, or are ineligible for ESA." https://www.sec.gov/Archives/edgar/data/886744/000088674426000037/gern-20260630.htm
- SEC Form 10-Q (accession 0000886744-26-000032): "On June 6, 2024, we announced that the FDA approved RYTELO for the treatment of adult patients with lower-risk MDS, with TD anemia requiring four or more red blood cell units over eight weeks who have not responded to, or have lost response to, or are ineligible for ESA." https://www.sec.gov/Archives/edgar/data/886744/000088674426000032/gern-20260331.htm
- SEC Form 10-K (accession 0000886744-26-000008): "On June 6, 2024, we announced that the FDA approved RYTELO for the treatment of adult patients with lower-risk MDS, with TD anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for ESA." https://www.sec.gov/Archives/edgar/data/886744/000088674426000008/gern-20251231.htm
- SEC Form 10-Q (accession 0000886744-25-000071): "On June 6, 2024, we announced that the FDA approved RYTELO for the treatment of adult patients with lower-risk MDS, with TD anemia requiring four or more red blood cell units over eight weeks who have not responded to, or have lost response to, or are ineligible for ESAs." https://www.sec.gov/Archives/edgar/data/886744/000088674425000071/gern-20250930.htm
- SEC Form 10-Q (accession 0000886744-25-000052): "On June 6, 2024, we announced that the FDA approved RYTELO for the treatment of adult patients with lower-risk MDS, with TD anemia requiring four or more red blood cell units over eight weeks who have not responded to, or have lost response to, or are ineligible for ESAs." https://www.sec.gov/Archives/edgar/data/886744/000088674425000052/gern-20250630.htm
- SEC Form 10-Q (accession 0000886744-25-000010): "On June 6, 2024, we announced that the FDA approved RYTELO for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes, or lower-risk MDS, with transfusion-dependent, or TD, anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents, or ESA." https://www.sec.gov/Archives/edgar/data/886744/000088674425000010/gern-20250331.htm
- Press release filed with the SEC (EX-99) (accession 0000886744-25-000048): "The increase in revenue is due to product revenue from U.S. sales of RYTELO, which was approved by the FDA in June 2024." https://www.sec.gov/Archives/edgar/data/886744/000088674425000048/gern-20250630xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0000886744-25-000007): "The increase in revenue is due to product revenue from U.S. sales of RYTELO, which was approved by the FDA in June 2024." https://www.sec.gov/Archives/edgar/data/886744/000088674425000007/gern-20250331xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-027331): "The increase in revenue is due to product revenue from U.S. sales of RYTELO, which was approved by the FDA in June 2024." https://www.sec.gov/Archives/edgar/data/886744/000095017025027331/gern-ex99_1.htm

### March 31, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-05-07, last confirmed 2025-05-07.
- SEC Form 10-Q (accession 0000886744-25-000010): "The decrease in research and development expenses for the three months ended March 31, 2025, compared to the same period in 2024, was primarily due to decreased clinical trial costs associated with a decrease of activity in our IMerge MDS study after FDA approval of RYTELO in 2024, as well as manufacturing and quality costs that were capitalized in the current period now that RYTELO is approved, versus being expensed in the prior period." https://www.sec.gov/Archives/edgar/data/886744/000088674425000010/gern-20250331.htm

### June 30, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Stage: 3.
- First seen 2025-08-06, last confirmed 2025-08-06.
- Press release filed with the SEC (EX-99) (accession 0000886744-25-000048): "Total product revenue, net for the three and six months ended June 30, 2025, was $49.0 million and $88.4 million, compared to $780,000 for the three and six months ended June 30, 2024, as RYTELO was approved by the FDA in June 2024." https://www.sec.gov/Archives/edgar/data/886744/000088674425000048/gern-20250630xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0000886744-25-000048): "The decrease in research and development expenses for the three and six months ended June 30, 2025, compared to the same periods in 2024, was primarily due to decreased clinical trial costs associated with a decrease of activity in our Phase 3 IMerge LR-MDS study after FDA approval of RYTELO in 2024, as well as manufacturing and quality costs that were capitalized in the current period now that RYTELO is approved, compared to being expensed in the prior period." https://www.sec.gov/Archives/edgar/data/886744/000088674425000048/gern-20250630xexx991.htm
- SEC Form 10-Q (accession 0000886744-25-000052): "The decrease in research and development expenses for the three and six months ended June 30, 2025, compared to the same periods in 2024, was primarily due to decreased clinical trial costs associated with a decrease of activity in our Phase 3 IMerge MDS study after FDA approval of RYTELO in 2024, as well as manufacturing and quality costs that were capitalized in the current period now that RYTELO is approved, versus being expensed in the prior period." https://www.sec.gov/Archives/edgar/data/886744/000088674425000052/gern-20250630.htm

### September 30, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Stage: 3.
- First seen 2025-11-07, last confirmed 2025-11-07.
- SEC Form 10-Q (accession 0000886744-25-000071): "The decrease in research and development expenses for the nine months ended September 30, 2025, compared to the same period in 2024, was primarily due to decreased clinical trial costs associated with a decrease of activity in our Phase 3 IMerge MDS study after FDA approval of RYTELO in 2024, as well as manufacturing and quality costs that were capitalized in the current period now that RYTELO is approved, versus being expensed in the prior period." https://www.sec.gov/Archives/edgar/data/886744/000088674425000071/gern-20250930.htm

### 2H 2026: interim data readout

- Status: scheduled. Date confidence: half. Stage: 3. Indication: JAKi relapsed/refractory myelofibrosis.
- First seen 2025-02-26, last confirmed 2026-08-05.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-068523): "In the second half of 2026, we look forward to the IMpactMF interim analysis in relapsed/refractory myelofibrosis and the first data from real-world experience trials focused on the use of RYTELO in LR-MDS." https://www.sec.gov/Archives/edgar/data/886744/000119312526068523/d67820dex991.htm
- Press release filed with the SEC (EX-99) (accession 0000886744-25-000068): "•Expect IMpactMF interim analysis readout for overall survival in the second half of 2026 (when approximately 35% of patient events have occurred), and final analysis in the second half of 2028 (when approximately 50% of patient events have occurred)." https://www.sec.gov/Archives/edgar/data/886744/000088674425000068/gern-20250930xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0000886744-25-000007): "We continue to expect an interim analysis readout for overall survival in the second half of 2026 (when approximately 35% of patient events have occurred), and final analysis in the second half of 2028 (when approximately 50% of patient events have occurred)." https://www.sec.gov/Archives/edgar/data/886744/000088674425000007/gern-20250331xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-068523): "Initial data is expected in the second half of 2026." https://www.sec.gov/Archives/edgar/data/886744/000119312526068523/d67820dex991.htm
- Press release filed with the SEC (EX-99) (accession 0000886744-26-000003): "15 INT-1/INT-2/HR MF: Intermediate-1/Intermediate-2/High Risk MF; PROs: patient-reported outcomes; SVR: spleen volume reduction; TSS: total symptom score. * Expect IMpactMF interim analysis readout for overall survival in the second half of 2026 (when approximately 35% of patient events have occurred), and final analysis in the second half of 2028 (when approximately 50% of patient events have occurred)." https://www.sec.gov/Archives/edgar/data/886744/000088674426000003/geroncorporatedeck-janua.htm
- Press release filed with the SEC (EX-99) (accession 0000886744-25-000048): "•Interim analysis readout for overall survival expected in the second half of 2026 (when approximately 35% of patient events have occurred), and final analysis expected in the second half of 2028 (when approximately 50% of patient events have occurred)." https://www.sec.gov/Archives/edgar/data/886744/000088674425000048/gern-20250630xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-027331): "(vi) that the interim analysis of IMpactMF is expected in the second half of 2026 and the final analysis is expected in the second half of 2028" https://www.sec.gov/Archives/edgar/data/886744/000095017025027331/gern-ex99_1.htm
- SEC Form 10-Q (accession 0000886744-26-000037): "Based on our current planning assumptions for event (death) rates in the trial, we expect the interim analysis for OS in IMpactMF may occur in the second half of 2026 and the final analysis may occur in the second half of 2028." https://www.sec.gov/Archives/edgar/data/886744/000088674426000037/gern-20260630.htm
- SEC Form 10-Q (accession 0000886744-26-000032): "Based on our current planning assumptions for event (death) rates in the trial, we expect the interim analysis for OS in IMpactMF may occur in the second half of 2026 and the final analysis may occur in the second half of 2028." https://www.sec.gov/Archives/edgar/data/886744/000088674426000032/gern-20260331.htm
- SEC Form 10-K (accession 0000950170-25-027982): "Based on our current planning assumptions for enrollment and event (death) rates in the trial, we expect the interim analysis for OS in IMpactMF may occur in the second half of 2026 and the final analysis may occur in the second half of 2028." https://www.sec.gov/Archives/edgar/data/886744/000095017025027982/gern-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0000886744-25-000007): "Looking ahead, our Phase 3 IMpactMF trial evaluating overall survival with imetelstat in patients with JAKi relapsed/refractory myelofibrosis (R/R MF), which we believe represents a tremendous expansion opportunity, is progressing well and the event-driven interim analysis is still expected in the second half of 2026."" https://www.sec.gov/Archives/edgar/data/886744/000088674425000007/gern-20250331xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0000886744-25-000007): "Reached approximately 85% enrollment in the Phase 3 IMpactMF clinical trial for treatment of relapsed/refractory myelofibrosis; interim analysis remains expected in 2H 2026" https://www.sec.gov/Archives/edgar/data/886744/000088674425000007/gern-20250331xexx991.htm

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Myelofibrosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04576156 (A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Geron Corporation." https://clinicaltrials.gov/study/NCT04576156

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Myelofibrosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04576156 (A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Geron Corporation." https://clinicaltrials.gov/study/NCT04576156

## Same indication

- [Elritercept](https://sec-api.dev/pdufa/elritercept) (TAK)
- [Itacitinib](https://sec-api.dev/pdufa/itacitinib) (INCY)

Calendar months: [June 2028](https://sec-api.dev/fda-calendar/2028-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/imetelstat.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "RYTELO (imetelstat) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/imetelstat

```bibtex
@misc{secapidev_pdufa_imetelstat_20261116,
  title        = {RYTELO (imetelstat) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/imetelstat}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_imetelstat_20261116","title":"RYTELO (imetelstat) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/imetelstat","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
